MindMed Announces Transitions to Management Team Post published:December 29, 2021 Post category:Press Release
MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder Post published:December 21, 2021 Post category:Press Release
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD Post published:December 17, 2021 Post category:Press Release
MindMed Appoints Robert Barrow as Chief Executive Officer and Director Post published:December 14, 2021 Post category:Press Release
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System Post published:December 9, 2021 Post category:Press Release
MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin Post published:November 30, 2021 Post category:Press Release
MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures Post published:November 16, 2021 Post category:Press Release
MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline Post published:November 15, 2021 Post category:Press Release
MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board Post published:November 5, 2021 Post category:Press Release
MindMed Announces R(-)-MDMA Program to target Social Anxiety Associated with Autism Spectrum Disorder Post published:October 26, 2021 Post category:Press Release